MAR
Neutral signalScored 2026-10-06 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Marriott International, Inc.
- Nom
- Marriott International, Inc.
- Secteur
- Consumer Cyclical
- Industrie
- Travel Lodging
- Bourse
- NASDAQ
- Capitalisation
- $102.0B
- Employés
- 414,000
- PDG
- Anthony G. Capuano Jr.
- Site web
- https://www.marriott.com
- Marché
- ACCYYATATCHHHHLTHTHT
Marriott International, Inc. is a leading global hospitality firm responsible for managing, franchising, and licensing a wide range of accommodation options, including hotels, residential units, and timeshare resorts, on an international scale. The company segments its extensive operations into North America (covering the U.S. and Canada) and its various international divisions. Under its corporate umbrella, Marriott oversees a diverse collection of esteemed brands, such as JW Marriott, The Ritz-Carlton, W Hotels, Sheraton, Westin, and Courtyard, among many others. As of February 15, 2022, its impressive network encompassed nearly 8,000 properties—specifically 7,989 establishments—operating across 139 countries and territories under 30 distinct hotel brand names. Established in 1927, Marriott International, Inc. maintains its corporate headquarters in Bethesda, Maryland.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-01-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-23 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-03-14 | Susie Lee | Sale (Full) | $1,001 - $15,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-08-02 | Josh S. Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2024-07-09 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-06-28 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-06-07 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-05-24 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2024-05-14 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2024-05-03 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2024-05-03 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2024-03-25 | Michael T. McCaul | Exchange | $100,001 - $250,000 |
| 2024-03-25 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2024-03-25 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2024-03-20 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2024-03-20 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2024-03-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-03-13 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-02-21 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2024-02-21 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2024-01-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-10-11 | Jonathan Jackson | Purchase | $15,001 - $50,000 |
| 2023-09-08 | Lois Frankel | Sale (Full) | $1,001 - $15,000 |
| 2023-08-16 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2023-08-16 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2023-07-13 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-06-06 | Jonathan Jackson | Purchase | $15,001 - $50,000 |
| 2023-05-10 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-05-10 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-02-15 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-02-15 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-02-06 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-02-06 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2022-12-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-02 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2022-12-02 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2022-11-16 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2022-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-02 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2022-11-02 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2022-10-21 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-07 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2022-09-07 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2022-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-08-04 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-08-04 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-07-19 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-26 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2022-04-21 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-04-21 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-04-14 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2022-04-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-03-09 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2021-12-15 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2021-09-24 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2021-09-23 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2020-09-15 | Joseph P. Kennedy | Sale (Full) | $1,001 - $15,000 |
| 2020-08-21 | Thomas Suozzi | Sale (Full) | $1,001 - $15,000 |
| 2020-07-08 | Susie Lee | Sale (Full) | $15,001 - $50,000 |
| 2020-07-06 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2020-06-15 | Thomas Suozzi | Purchase | $1,001 - $15,000 |
| 2020-05-14 | Rick W. Allen | Purchase | $15,001 - $50,000 |
| 2020-04-29 | Mo Brooks | Sale (Full) | $15,001 - $50,000 |
| 2020-04-17 | Stephen Cohen | Sale (Full) | $1,001 - $15,000 |
| 2019-10-17 | Rick W. Allen | Sale (Full) | $15,001 - $50,000 |
| 2019-08-22 | Rick W. Allen | Purchase | $15,001 - $50,000 |
| 2019-05-23 | David Eugene Price | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
MAR presents a structurally weak financial profile with a liquidity score of 35, driven by negative equity, a debt-to-capital ratio above 1.0, and a current ratio below 0.5, leaving virtually no margin of safety.
The first sentence of the analysis written for MAR on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 0.43 · operating margin 16% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 21.3% | 20.3% | 21.6% | 21.9% | 20.2% | |
| Ebit Margin | 16.0% | 15.3% | 16.6% | 16.9% | 11.5% | |
| Ebitda Margin | 17.1% | 17.3% | 18.5% | 18.9% | 13.7% | |
| Operating Profit Margin | 15.8% | 15.0% | 16.3% | 16.7% | 12.6% | |
| Pretax Profit Margin | 13.0% | 12.6% | 14.2% | 15.0% | 8.5% | |
| Continuous Operations Profit Margin | 9.9% | 9.5% | 13.0% | 11.4% | 7.9% | |
| Net Profit Margin | 9.9% | 9.5% | 13.0% | 11.4% | 7.9% | |
| Bottom Line Profit Margin | 9.9% | 9.5% | 13.0% | 11.4% | 7.9% | |
| Current Ratio | 0.427 | 0.403 | 0.427 | 0.451 | 0.566 | |
| Quick Ratio | 0.427 | 0.403 | 0.427 | 0.451 | 0.566 | |
| Solvency Ratio | 0.093 | 0.098 | 0.134 | 0.114 | 0.058 | |
| Cash Ratio | 0.043 | 0.046 | 0.044 | 0.069 | 0.217 | |
| Price To Earnings Ratio | 32.588 | 33.366 | 22.044 | 20.480 | 49.179 | |
| Price To Earnings Growth Ratio | 2.349 | -1.825 | 0.541 | 0.176 | -0.096 | |
| Forward Price To Earnings Growth Ratio | 2.349 | -1.825 | 0.541 | 0.176 | -0.096 | |
| Price To Earnings Diluted Ratio | 32.691 | 33.486 | 22.152 | 20.565 | 49.473 | |
| Price To Earnings Diluted Growth Ratio | 2.348 | -1.843 | 0.546 | 0.176 | -0.098 | |
| Price To Book Ratio | -22.089 | -26.496 | -99.694 | 85.035 | 38.237 | |
| Price To Sales Ratio | 3.181 | 3.158 | 2.867 | 2.325 | 3.902 | |
| Price To Free Cash Flow Ratio | 31.940 | 39.657 | 25.015 | 23.781 | 54.393 | |
| Price To Operating Cash Flow Ratio | 25.934 | 28.838 | 21.448 | 20.440 | 45.936 | |
| Debt To Assets Ratio | 0.620 | 0.582 | 0.497 | 0.447 | 0.440 | |
| Debt To Equity Ratio | -4.530 | -5.094 | -18.710 | 19.539 | 7.946 | |
| Debt To Capital Ratio | 1.283 | 1.244 | 1.056 | 0.951 | 0.888 | |
| Long Term Debt To Capital Ratio | 1.336 | 1.295 | 1.064 | 0.943 | 0.868 | |
| Financial Leverage Ratio | -7.303 | -8.751 | -37.645 | 43.688 | 18.071 | |
| Working Capital Turnover Ratio | -5.249 | -5.221 | -5.595 | -6.103 | -4.855 | |
| Operating Cash Flow Ratio | 0.382 | 0.318 | 0.408 | 0.322 | 0.184 | |
| Operating Cash Flow Sales Ratio | 0.123 | 0.110 | 0.134 | 0.114 | 0.085 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.812 | 0.727 | 0.857 | 0.860 | 0.845 | |
| Debt Service Coverage Ratio | 1.831 | 1.777 | 3.653 | 2.908 | 1.481 | |
| Interest Coverage Ratio | 5.119 | 5.420 | 6.839 | 8.591 | 4.167 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.657 | 2.100 | 5.732 | 3.455 | 1.462 | |
| Operating Cash Flow Coverage Ratio | 0.188 | 0.180 | 0.248 | 0.213 | 0.105 | |
| Capital Expenditure Coverage Ratio | 5.318 | 3.665 | 7.013 | 7.117 | 6.432 | |
| Dividend Paid And Capex Coverage Ratio | 2.430 | 1.920 | 3.051 | 3.619 | 6.432 | |
| Dividend Payout Ratio | 0.276 | 0.287 | 0.190 | 0.136 | 0.000 | |
| Enterprise Value Multiple | 22.287 | 21.697 | 18.363 | 15.035 | 33.725 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 21.3% | ▲1.0% | ▲0.2% |
| Ebit Margin | 16.0% | ▲0.7% | ▲0.7% |
| Ebitda Margin | 17.1% | ▼-0.1% | ▲0.1% |
| Operating Profit Margin | 15.8% | ▲0.8% | ▲0.5% |
| Pretax Profit Margin | 13.0% | ▲0.4% | ▲0.3% |
| Continuous Operations Profit Margin | 9.9% | ▲0.5% | ▼-0.4% |
| Net Profit Margin | 9.9% | ▲0.5% | ▼-0.4% |
| Bottom Line Profit Margin | 9.9% | ▲0.5% | ▼-0.4% |
| Current Ratio | 0.427 | ▲0.024 | ▼-0.028 |
| Quick Ratio | 0.427 | ▲0.024 | ▼-0.028 |
| Solvency Ratio | 0.093 | ▼-0.006 | ▼-0.007 |
| Cash Ratio | 0.043 | ▼-0.003 | ▼-0.041 |
| Price To Earnings Ratio | 32.588 | ▼-0.778 | ▲1.057 |
| Price To Earnings Growth Ratio | 2.349 | ▲4.174 | ▲2.120 |
| Forward Price To Earnings Growth Ratio | 2.349 | ▲4.174 | ▲2.120 |
| Price To Earnings Diluted Ratio | 32.691 | ▼-0.795 | ▲1.018 |
| Price To Earnings Diluted Growth Ratio | 2.348 | ▲4.190 | ▲2.122 |
| Price To Book Ratio | -22.090 | ▲4.406 | ▼-17.088 |
| Price To Sales Ratio | 3.181 | ▲0.023 | ▲0.094 |
| Price To Free Cash Flow Ratio | 31.940 | ▼-7.717 | ▼-3.017 |
| Price To Operating Cash Flow Ratio | 25.934 | ▼-2.904 | ▼-2.585 |
| Debt To Assets Ratio | 0.620 | ▲0.038 | ▲0.103 |
| Debt To Equity Ratio | -4.530 | ▲0.564 | ▼-4.360 |
| Debt To Capital Ratio | 1.283 | ▲0.039 | ▲0.199 |
| Long Term Debt To Capital Ratio | 1.336 | ▲0.041 | ▲0.235 |
| Financial Leverage Ratio | -7.303 | ▲1.448 | ▼-8.915 |
| Working Capital Turnover Ratio | -5.249 | ▼-0.028 | ▲0.156 |
| Operating Cash Flow Ratio | 0.383 | ▲0.065 | ▲0.060 |
| Operating Cash Flow Sales Ratio | 0.123 | ▲0.013 | ▲0.010 |
| Free Cash Flow Operating Cash Flow Ratio | 0.812 | ▲0.085 | ▼-0.008 |
| Debt Service Coverage Ratio | 1.831 | ▲0.054 | ▼-0.499 |
| Interest Coverage Ratio | 5.119 | ▼-0.301 | ▼-0.908 |
| Short Term Operating Cash Flow Coverage Ratio | 2.657 | ▲0.557 | ▼-0.424 |
| Operating Cash Flow Coverage Ratio | 0.188 | ▲0.008 | ▲0.001 |
| Capital Expenditure Coverage Ratio | 5.318 | ▲1.653 | ▼-0.591 |
| Dividend Paid And Capex Coverage Ratio | 2.430 | ▲0.510 | ▼-1.060 |
| Dividend Payout Ratio | 0.276 | ▼-0.011 | ▲0.098 |
| Enterprise Value Multiple | 22.287 | ▲0.591 | ▲0.066 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $83.30B | $79.27B | $67.99B | $48.30B | $54.07B | |
| Enterprise value | $100.02B | $94.12B | $80.41B | $58.89B | $63.91B | |
| EV / Sales | 3.82x | 3.75x | 3.39x | 2.83x | 4.61x | |
| EV / Op. cash flow | 31.14x | 34.24x | 25.37x | 24.92x | 54.30x | |
| EV / Free cash flow | 38.35x | 47.08x | 29.59x | 29.00x | 64.30x | |
| EV / EBITDA | 22.29x | 21.70x | 18.36x | 15.04x | 33.73x | |
| Net debt / EBITDA | 3.73x | 3.42x | 2.84x | 2.70x | 5.19x | |
| Current ratio | 0.43x | 0.40x | 0.43x | 0.45x | 0.57x | |
| Income quality | 1.24x | 1.16x | 1.03x | 1.00x | 1.07x | |
| Graham number | — | — | — | $17 | $18 | |
| Graham net-net | -$107 | -$94 | -$80 | -$67 | -$65 | |
| Tax burden | 76.6% | 75.4% | 91.3% | 75.7% | 93.1% | |
| Interest burden | 81.0% | 81.9% | 85.7% | 88.5% | 73.8% | |
| Working capital | -$4.81B | -$5.16B | -$4.45B | -$4.03B | -$2.78B | |
| Invested capital | $17.32B | $15.73B | $16.14B | $16.16B | $17.78B | |
| Return on assets | 9.4% | 9.1% | 12.0% | 9.5% | 4.3% | |
| Operating ROA | 15.4% | 14.5% | 15.3% | 13.7% | 7.0% | |
| Return on tangible assets | 31.3% | 29.8% | 40.6% | 32.8% | 14.5% | |
| Return on equity | -69.0% | -79.4% | -452.1% | 415.1% | 77.7% | |
| Return on invested capital | 15.6% | 15.1% | 19.1% | 14.4% | 8.2% | |
| Return on capital employed | 21.6% | 21.5% | 21.6% | 19.8% | 9.1% | |
| Earnings yield | 3.1% | 3.0% | 4.5% | 4.9% | 2.0% | |
| Free cash flow yield | 3.1% | 2.5% | 4.0% | 4.2% | 1.8% | |
| Capex / Op. cash flow | 18.8% | 27.3% | 14.3% | 14.0% | 15.5% | |
| Capex / Depreciation | 100.8% | 152.4% | 103.7% | 83.0% | 62.0% | |
| Capex / Sales | 2.3% | 3.0% | 1.9% | 1.6% | 1.3% | |
| SG&A / Sales | 3.7% | 4.3% | 4.3% | 4.3% | 5.9% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.9% | 0.9% | 0.9% | 0.9% | 1.3% | |
| Intangibles / Total assets | 69.9% | 69.6% | 70.4% | 71.0% | 70.4% | |
| Days sales outstanding | 41d | 41d | 42d | 45d | 52d | |
| Days payables outstanding | 14d | 14d | 14d | 17d | 24d | |
| Operating cycle | 41d | 41d | 42d | 45d | 52d | |
| Cash conversion cycle | 26d | 27d | 27d | 28d | 28d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+5.1%EV / Sales ▲+1.9%EV / EBITDA ▲+2.7%EV / Op. cash flow ▼-3.097Earnings yield ▲+0.001
Profitability
Return on equity ▲+0.104Return on assets ▲+0.004Return on invested capital ▲+0.005Return on capital employed ▲+0.001Operating ROA ▲+0.009Income quality ▲+0.077Tax burden ▲+0.013
Efficiency
Days sales outstanding ▼-0.097Days payables outstanding ▲+0.498Operating cycle ▼-0.097Cash conversion cycle ▼-0.595Capex / Sales ▼-0.007R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.024Net debt / EBITDA ▲+0.305Working capital ▲+350000000.000Invested capital ▲+1591000000.000Intangibles / Total assets ▲+0.003
Change over 5 years
Valuation
Market cap ▲+54.1%EV / Sales ▼-17.2%EV / EBITDA ▼-33.9%EV / Op. cash flow ▼-23.158Earnings yield ▲+0.011
Profitability
Return on equity ▼-1.467Return on assets ▲+0.051Return on invested capital ▲+0.074Return on capital employed ▲+0.125Operating ROA ▲+0.085Income quality ▲+0.164Tax burden ▼-0.165
Efficiency
Days sales outstanding ▼-11.659Days payables outstanding ▼-9.544Operating cycle ▼-11.659Cash conversion cycle ▼-2.115Capex / Sales ▲+0.010R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.139Net debt / EBITDA ▼-1.468Working capital ▼-2033000000.000Invested capital ▼-459000000.000Intangibles / Total assets ▼-0.006
Employee count
Peer market caps
Recent news
- 2026-10-06 The Rise of Place: Marriott International Reveals Asia Pacific''s Future of Food Local cuisine emerges as the region''s strongest dining force, as traditional restaurant settings give way to fluid, social spaces. SINGAPORE, Oct. 6, 2026 /PRNewswire/ -- Marriott International has unveiled Future of Food 2027, its latest report exploring food and beverage trends across Asia Pacific excluding China.
- 2026-10-05 THE RITZ-CARLTON NAPLES, TIBURÓN REVEALS TRANSFORMED RESORT AND DYNAMIC CULINARY CONCEPTS Refreshed accommodations, light-filled public spaces, and vibrant culinary debuts an enriched resort experience grounded in nature, play, and community. NAPLES, Fla.
- 2026-10-05 Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) subsidiary Marea Therapeutics has dosed the first patient in a Phase 2 clinical trial of MAR002, a first-in-class antibody therapy for acromegaly, the company said on Monday. Marea, which is developing medicines for cardioendocrine diseases, is advancing MAR002 as a potential new option for the rare endocrine disorder.
- 2026-10-05 Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care
- 2026-09-28 Forget Inflation: Funflation Is Here and These ETFs Are Riding on It ETFs like AWAY are riding on "funflation" as consumers keep spending on hobbies, travel, music and leisure despite higher prices.
- 2026-09-24 Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026 SOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that data from the Phase 2b TYDAL study of MAR001, a potential first-in-class monoclonal antibody targeting angiopoietin-like protein 4 (ANGPTL4), will be presented in a late-breaking science session at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9, 2026, in Chicago, Illinois.
- 2026-09-10 Allworth Financial LP Has $5.55 Million Stock Holdings in Marriott International, Inc. $MAR Allworth Financial LP trimmed its holdings in Marriott International, Inc. (NASDAQ: MAR) by 39.6% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,976 shares of the company''s stock after selling 9,812 shares during the period. Allworth Financial LP''s holdings in Marriott
- 2026-09-09 Marriott International, Inc. (MAR) Presents at Bank of America Gaming and Lodging Conference 2026 Transcript Marriott International, Inc. (MAR) Presents at Bank of America Gaming and Lodging Conference 2026 Transcript
- 2026-09-09 The Ritz-Carlton Yacht Collection Introduces Its Summer 2028 Mediterranean & Northern Europe Season Thoughtfully designed voyages across Europe balance iconic destinations with quieter coastal communities, creating space for unexpected moments of discovery along the way. FORT LAUDERDALE, Fla.
- 2026-09-07 California State Teachers Retirement System Has $42.45 Billion Position in Marriott International, Inc. $MAR California State Teachers Retirement System lifted its position in Marriott International, Inc. (NASDAQ: MAR) by 43,255.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 114,540,104 shares of the company''s stock after acquiring an additional 114,275,918 shares during the period. California